Extensive development program in wide range of tumors

BO-112 is being explored as a monotherapy and in combination as part of an extensive development program, both in-house and led by external investigators in different settings.

A successful Phase 1 clinical trial as monotherapy and a successful phase 1b clinical trial in combination with anti-PD1 have been completed.

Highlight and Merck, known as MSD outside the U.S. and Canada, completed a successful Phase 2 study  to evaluate intra-tumoral administration of BO-112 + pembrolizumab in mucosal, acral and cutaneous melanoma patients in August 2021. Initiation of a randomized Phase 2 study in 2nd-line melanoma is planned in 2022.

Positive results from a pre-clinical study  of intratumoral administration of BO-112 with a STING agonist by Highlight and Cima Universidad de Navarra were published in the Journal for ImmunoTherapy of Cancer in December 2021.